Profile data is unavailable for this security.
About the company
Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.
- Revenue in CAD (TTM)0.00
- Net income in CAD-30.22m
- Incorporated2017
- Employees17.00
- LocationCardiol Therapeutics Inc602-2265 Upper Middle Road EastOAKVILLE L6H 0G5CanadaCAN
- Phone+1 (289) 910-0850
- Fax+1 (905) 491-6793
- Websitehttps://www.cardiolrx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncolytics Biotech Inc | 0.00 | -28.21m | 112.98m | 29.00 | -- | 4.83 | -- | -- | -0.4027 | -0.4027 | 0.00 | 0.3046 | 0.00 | -- | -- | -- | -80.51 | -81.99 | -88.84 | -97.25 | -- | -- | -- | -- | -- | -- | 0.0468 | -- | -- | -- | -11.75 | -- | -40.52 | -- |
| Zentek Ltd | 29.82k | -11.70m | 136.62m | 25.00 | -- | 6.75 | -- | 4,581.54 | -0.1167 | -0.1167 | 0.0003 | 0.2001 | 0.0011 | 0.155 | 0.0689 | 1,192.80 | -41.89 | -47.65 | -45.33 | -51.12 | -1,010.23 | -- | -39,248.79 | -13,980.33 | 2.65 | -- | 0.058 | -- | -59.07 | -- | 18.80 | -- | -19.38 | -- |
| Eupraxia Pharmaceuticals Inc | 0.00 | -42.38m | 138.75m | 29.00 | -- | 5.12 | -- | -- | -1.68 | -1.68 | 0.00 | 0.7599 | 0.00 | -- | -- | 0.00 | -122.29 | -127.84 | -185.74 | -935.99 | -- | -- | -- | -- | -- | -85.63 | 0.3455 | -- | -- | -- | -52.63 | -- | -7.69 | -- |
| Medicenna Therapeutics Corp | 0.00 | -25.47m | 157.66m | 16.00 | -- | 27.63 | -- | -- | -0.3657 | -0.3657 | 0.00 | 0.0745 | 0.00 | -- | -- | 0.00 | -91.64 | -54.93 | -104.12 | -60.91 | -- | -- | -- | -- | -- | -2.75 | 0.00 | -- | -- | -- | -153.44 | -- | -- | -- |
| NervGen Pharma Corp | 0.00 | -20.02m | 196.76m | 10.00 | -- | 10.40 | -- | -- | -0.3363 | -0.3363 | 0.00 | 0.2692 | 0.00 | -- | -- | -- | -78.68 | -121.15 | -138.24 | -180.20 | -- | -- | -- | -- | -- | -9.07 | 0.0092 | -- | -- | -- | -8.01 | -- | 2.20 | -- |
| Cardiol Therapeutics Inc | 0.00 | -30.22m | 217.26m | 17.00 | -- | 10.65 | -- | -- | -0.4622 | -0.4622 | 0.00 | 0.2938 | 0.00 | -- | -- | -- | -72.11 | -58.97 | -91.89 | -68.62 | -- | -- | -- | -158,738.10 | -- | -- | 0.0083 | -- | -- | -- | 9.06 | -- | 36.06 | -- |
| Holder | Shares | % Held |
|---|---|---|
| MM Asset Management, Inc.as of 31 Mar 2024 | 2.57m | 3.72% |
| Tejara Capital Ltd.as of 31 Mar 2024 | 1.64m | 2.38% |
| AdvisorShares Investments LLCas of 05 Jul 2024 | 1.47m | 2.13% |
| Lion Street Advisors LLCas of 30 Jun 2024 | 253.28k | 0.37% |
| Global X Investments Canada, Inc.as of 30 Jun 2024 | 157.35k | 0.23% |
| Cambridge Investment Research Advisors, Inc.as of 30 Jun 2024 | 116.13k | 0.17% |
| MGO One Seven LLCas of 31 Mar 2024 | 100.00k | 0.15% |
| LNW Wealth Management LLCas of 31 Mar 2024 | 100.00k | 0.15% |
| PMG Investment Solutions AGas of 31 Dec 2023 | 80.00k | 0.12% |
| Credit Suisse AGas of 31 Mar 2024 | 80.00k | 0.12% |
